We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With the last legal hurdle removed, Sandoz wasted no time launching its Zarxio biosimilar of Amgen’s chemotherapy product Neupogen nationwide — offering the first U.S. biosimilar at 15 percent below the price of its reference product. Read More
Sanofi will terminate its 19-month collaboration with Ardelyx, effective Sept. 30, ending an alliance that focused on developing NaP2b phosphate inhibitors for kidney disease. Read More
Sanofi will terminate its 19-month collaboration with Ardelyx, effective Sept. 30, ending an alliance that focused on developing NaP2b phosphate inhibitors for kidney disease. Read More
Amgen and Novartis have launched a neuroscience drug collaboration to develop and commercialize new inhibitors to fight Alzheimer’s disease and treat migraines. Read More
By a two to one vote, a Federal Circuit Court of Appeals panel cleared the way for Sandoz’s launch of Zarxio, the first FDA-approved biosimilar, as early as today. Read More
Valeant Pharmaceuticals will pay up to $445 million for the rights to AstraZeneca’s investigational psoriasis drug brodalumab, which is set for regulatory submissions in the U.S. and EU in the fourth quarter. Read More